# BFRI catalysts: Biofrontera Inc. PDUFA dates and FDA events

Canonical: https://sec-api.dev/companies/bfri/catalysts

> Biofrontera Inc. (BFRI) has no upcoming catalysts in this calendar. The latest recorded is the Biofrontera Inc. earnings report, November 13, 2026.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: exact day, month only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Company

| Field | Value |
| --- | --- |
| Name | Biofrontera Inc. |
| Ticker | BFRI (Nasdaq) |
| SEC CIK | 1858685 |
| SIC | 2834 |
| SEC filings | https://sec-api.dev/companies/bfri |

## Cash runway

Cash $3.2M as of 2026-09-30; quarterly burn $1.4M; about 6.7 months of runway at that rate (XBRL company facts, accession 0001493152-26-051781).

## Catalysts

| Date | Event | Ticker | Indication | Status | Source sentence |
| --- | --- | --- | --- | --- | --- |
| May 10, 2016 | [Ameluz (aminolevulinic acid hydrochloride) FDA approval](https://sec-api.dev/pdufa/aminolevulinic-acid) | BFRI |  | completed, approved | "NDA208081 ORIG-1 (Type 3 - New Dosage Form): submission_status AP, submission_status_date 20160510, review_priority STANDARD; sponsor_name BIOFRONTERA; product AMELUZ (AMINOLEVULINIC ACID HYDROCHLORIDE)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA208081%22)) |
| Oct 2024 | [Ameluz (ameluz) label expansion decision](https://sec-api.dev/pdufa/ameluz) | BFRI |  | completed, approved | "October 2024, the FDA approved the Company's Supplemental New Drug Application to increase the maximally approved dosage of Ameluz® from one to three tubes per treatment." ([SEC registration statement (S-1)](https://www.sec.gov/Archives/edgar/data/1858685/000149315225026443/forms-1.htm)) |
| October 4, 2024 | [Ameluz (aminolevulinic acid hydrochloride) label expansion decision](https://sec-api.dev/pdufa/aminolevulinic-acid) | BFRI |  | completed, approved | "NDA208081 SUPPL-28 (Efficacy): submission_status AP, submission_status_date 20241004, review_priority STANDARD; sponsor_name BIOFRONTERA; product AMELUZ (AMINOLEVULINIC ACID HYDROCHLORIDE)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA208081%22)) |
| November 13, 2024 | [Biofrontera Inc. earnings report](https://sec-api.dev/companies/bfri/catalysts) | BFRI |  | completed | "Inc. Reports Third Quarter and Nine-Month 2024 Financial Results and Provides Business Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1858685/000149315224045205/ex99-1.htm)) |
| March 21, 2025 | [Biofrontera Inc. earnings report](https://sec-api.dev/companies/bfri/catalysts) | BFRI |  | completed | "Inc. Reports Record Fiscal Year 2024 Financial Results and Provides a Business Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1858685/000149315225011083/ex99-1.htm)) |
| May 15, 2025 | [Biofrontera Inc. earnings report](https://sec-api.dev/companies/bfri/catalysts) | BFRI |  | completed | "Inc. Reports First Quarter 2025 Financial Results and Provides a Business Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1858685/000164117225011069/ex99-1.htm)) |
| August 13, 2025 | [Biofrontera Inc. earnings report](https://sec-api.dev/companies/bfri/catalysts) | BFRI |  | completed | "Inc. Reports Second Quarter 2025 Financial Results and Provides a Business Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1858685/000164117225023598/ex99-1.htm)) |
| August 22, 2025 | [1h incubation photodynamic therapy (pdt) (ala-pdt, ameluz®-pdt) primary completion](https://sec-api.dev/pdufa/1h-incubation-photodynamic-therapy-pdt-ala-pdt-ameluz-pdt) | BFRI | Acne Vulgaris | completed | "NCT05080764 (Study to Evaluate the Safety and Efficacy of BF-200 ALA (Ameluz®) and BF-RhodoLED® in the Treatment of Moderate to Severe Acne Vulgaris With Photodynamic Therapy in Adults): Overall Status COMPLETED; Phase PHASE2; Primary Completion 2025-08-22 (ACTUAL); Lead Sponsor Biofrontera Inc.; Results First Posted 2026-10-01." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05080764)) |
| September 3, 2025 | [Bf-200 ala and red light led lamp primary completion](https://sec-api.dev/pdufa/bf-200-ala-and-red-light-led-lamp) | BFRI | Actinic Keratoses | completed | "NCT05662202 (Study to Evaluate the Safety, Tolerability and Efficacy of BF-200 ALA (Ameluz®) in the Field-directed Treatment of Actinic Keratosis (AK) on the Extremities and Neck/Trunk With Photodynamic Therapy (PDT) Using a RhodoLED Lamp): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2025-09-03 (ACTUAL); Lead Sponsor Biofrontera Inc.; Results First Posted 2026-08-21." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05662202)) |
| November 13, 2025 | [Biofrontera Inc. earnings report](https://sec-api.dev/companies/bfri/catalysts) | BFRI |  | completed | "Inc. Reports Third Quarter 2025 Financial Results and Provides a Business Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1858685/000149315225022133/ex99-1.htm)) |
| January 13, 2026 | [Biofrontera Inc. earnings report](https://sec-api.dev/companies/bfri/catalysts) | BFRI |  | completed | "(January 13, 2026) - Biofrontera Inc. (Nasdaq: BFRI) ("Biofrontera" or the "Company"), a leader in photodynamic therapy (PDT) development and commercialization, today announced preliminary unaudited revenue results for the fourth quarter ended December 31, 2025." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1858685/000149315226001959/ex99-1.htm)) |
| February 9, 2026 | [Ameluz (ameluz) topline data readout](https://sec-api.dev/pdufa/ameluz) | BFRI |  | completed, met | "(February 9, 2026) — Biofrontera Inc. (Nasdaq: BFRI) ("Biofrontera" or the "Company"), a biopharmaceutical company specializing in the development and commercialization of photodynamic therapy (PDT), today announced positive and statistically significant top-line results from its Phase 3 clinical trial evaluating Ameluz® PDT with the red-light LED (RhodoLED®)" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1858685/000149315226005717/ex99-1.htm)) |
| March 19, 2026 | [Biofrontera Inc. earnings report](https://sec-api.dev/companies/bfri/catalysts) | BFRI |  | completed | "Inc. Reports Record Fourth Quarter and Full Year 2025 Financial Results and Provides a Business Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1858685/000149315226011545/ex99-1.htm)) |
| May 14, 2026 | [Biofrontera Inc. earnings report](https://sec-api.dev/companies/bfri/catalysts) | BFRI |  | completed | "Inc. Reports First Quarter 2026 Financial Results and Provides a Business Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1858685/000149315226022875/ex99-1.htm)) |
| August 13, 2026 | [Biofrontera Inc. earnings report](https://sec-api.dev/companies/bfri/catalysts) | BFRI |  | completed | "Inc. Reports Strong Second Quarter 2026 Financial Results Driven by 33% Revenue Growth" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1858685/000149315226037610/ex99-1.htm)) |
| August 21, 2026 | [Bf-200 ala and red light led lamp topline data readout](https://sec-api.dev/pdufa/bf-200-ala-and-red-light-led-lamp) | BFRI | Actinic Keratoses | completed | "NCT05662202 (Study to Evaluate the Safety, Tolerability and Efficacy of BF-200 ALA (Ameluz®) in the Field-directed Treatment of Actinic Keratosis (AK) on the Extremities and Neck/Trunk With Photodynamic Therapy (PDT) Using a RhodoLED Lamp): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2025-09-03 (ACTUAL); Lead Sponsor Biofrontera Inc.; Results First Posted 2026-08-21." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05662202?tab=results)) |
| Sep 2026 | [Biofrontera Inc. PDUFA date](https://sec-api.dev/companies/bfri/catalysts) | BFRI |  | scheduled | "With a PDUFA date for sBCC in September 2026, positive" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1858685/000149315226022875/ex99-1.htm)) |
| September 9, 2026 | [Ameluz (aminolevulinic acid hydrochloride) label expansion decision](https://sec-api.dev/pdufa/aminolevulinic-acid) | BFRI |  | completed, approved | "NDA208081 SUPPL-40 (Efficacy): submission_status AP, submission_status_date 20260909, review_priority STANDARD; sponsor_name BIOFRONTERA; product AMELUZ (AMINOLEVULINIC ACID HYDROCHLORIDE)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA208081%22)) |
| September 14, 2026 | [Ameluz (ameluz) FDA approval](https://sec-api.dev/pdufa/ameluz) | BFRI | Superficial Basal Cell Carcinoma | completed, approved | "Announces FDA Approval of Ameluz® Red Light PDT for the Treatment of Superficial Basal Cell Carcinoma" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1858685/000149315226042508/ex99-1.htm)) |
| September 14, 2026 | [Biofrontera Inc. label expansion decision](https://sec-api.dev/companies/bfri/catalysts) | BFRI |  | completed, approved | "September 14, 2026, Biofrontera Inc. (the "Company") issued a press release announcing that it has received notification from the U.S. Food and Drug Administration (the "FDA") that the FDA had approved the Company's supplemental New Drug" ([SEC Form 8-K](https://www.sec.gov/Archives/edgar/data/1858685/000149315226042508/form8-k.htm)) |
| October 1, 2026 | [1h incubation photodynamic therapy (pdt) (ala-pdt, ameluz®-pdt) topline data readout](https://sec-api.dev/pdufa/1h-incubation-photodynamic-therapy-pdt-ala-pdt-ameluz-pdt) | BFRI | Acne Vulgaris | completed | "NCT05080764 (Study to Evaluate the Safety and Efficacy of BF-200 ALA (Ameluz®) and BF-RhodoLED® in the Treatment of Moderate to Severe Acne Vulgaris With Photodynamic Therapy in Adults): Overall Status COMPLETED; Phase PHASE2; Primary Completion 2025-08-22 (ACTUAL); Lead Sponsor Biofrontera Inc.; Results First Posted 2026-10-01." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05080764?tab=results)) |
| November 13, 2026 | [Biofrontera Inc. earnings report](https://sec-api.dev/companies/bfri/catalysts) | BFRI |  | completed | "Inc. Reports Strong Third Quarter 2026 Financial Results Driven by 30% Year-Over-Year Revenue Growth" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1858685/000149315226051546/ex99-1.htm)) |

## Drugs

- [1h incubation photodynamic therapy (pdt) (ala-pdt, ameluz®-pdt)](https://sec-api.dev/pdufa/1h-incubation-photodynamic-therapy-pdt-ala-pdt-ameluz-pdt): Acne Vulgaris
- [Ameluz (ameluz)](https://sec-api.dev/pdufa/ameluz): superficial basal cell carcinoma, superficial basal
- [Ameluz (aminolevulinic acid hydrochloride)](https://sec-api.dev/pdufa/aminolevulinic-acid): 
- [Bf-200 ala and red light led lamp](https://sec-api.dev/pdufa/bf-200-ala-and-red-light-led-lamp): Actinic Keratoses

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/companies/bfri/catalysts.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "BFRI catalysts: Biofrontera Inc. PDUFA dates and FDA events." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/companies/bfri/catalysts

```bibtex
@misc{secapidev_companies_bfri_catalysts_20261116,
  title        = {BFRI catalysts: Biofrontera Inc. PDUFA dates and FDA events},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/companies/bfri/catalysts}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_companies_bfri_catalysts_20261116","title":"BFRI catalysts: Biofrontera Inc. PDUFA dates and FDA events","publisher":"sec-api.dev","URL":"https://sec-api.dev/companies/bfri/catalysts","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
